The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 (gersizangitide) injected suprachoroidally in patients with...
BALTIMORE, July 26, 2023 (GLOBE NEWSWIRE) -- AsclepiX Therapeutics, Inc., a clinical-stage biotech company leveraging computational biology from Johns Hopkins to identify and develop peptides for...
AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME).